Table 2. Cellular drug resistance in... | American Society of Hematology

Table 2.

Cellular drug resistance in patients with DS versus non-DS AML

Drug	DS AML		Non-DS AML		RR	P
Drug	N	Median (P25-P75)	N	Median (P25-P75)	RR	P
Cytarabine	13	0.04	143	0.46	11.5	<.001
		(0.02-0.11)		(0.24-1.21)
Daunorubicin	12	0.09	130	0.20	2.2	.005
		(0.05-0.10)		(0.09-0.38)
Idarubicin	8	0.017	94	0.122	7.2	.002
		(0.004-0.025)		(0.039-0.265)
Mitoxantrone	10	0.012	113	0.11	9.2	.002
		(0.005-0.04)		(0.03-0.35)
Etoposide	12	0.37	132	7.42	20.1	<.001
		(0.16-0.60)		(1.92-19.41)
6-Thioguanine	12	2.20	140	6.03	2.7	<.001
		(<1.56-2.81)		(4.05-10.54)
Amsacrine	8	0.03	115	0.48	16.0	<.001
		(0.02-0.08)		(0.14-1.32)
2-Chloro-deoxyadenosine	6	0.016	103	0.020	1.3	.42
		(0.004-0.023)		(0.04-0.031)
Prednisolone	10	231.6	146	>250	>1.1	.006
		(95.9->250)		(>250->250)
Vincristine	11	0.13	135	2.99	23.0	<.001
		(<0.05-0.17)		(0.75-23.92)
L-Asparaginase	10	0.76	123	0.88	1.2	.83
		(0.33-1.19)		(0.23-1.48)
Busulfan	6	8.2	93	37.78	4.6	<.001
		(6.1-13.7)		(25.59-59.82)
4-hydroperoxy-ifosfamide	8	10.12	116	11.93	1.2	.47
		(4.69-12.31)		(5.79-14.78)
Methotrexate (TSI₅₀ short)	11	38.32	28	1.82	0.05	.003
		(32.62->40)		(0.63-18.38)
Methotrexate (TSI₅₀ cont)	9	0.08	27	0.05	0.6	.22
		(0.04-0.13)		(0.03-0.06)

Drug	DS AML		Non-DS AML		RR	P
Drug	N	Median (P25-P75)	N	Median (P25-P75)	RR	P
Cytarabine	13	0.04	143	0.46	11.5	<.001
		(0.02-0.11)		(0.24-1.21)
Daunorubicin	12	0.09	130	0.20	2.2	.005
		(0.05-0.10)		(0.09-0.38)
Idarubicin	8	0.017	94	0.122	7.2	.002
		(0.004-0.025)		(0.039-0.265)
Mitoxantrone	10	0.012	113	0.11	9.2	.002
		(0.005-0.04)		(0.03-0.35)
Etoposide	12	0.37	132	7.42	20.1	<.001
		(0.16-0.60)		(1.92-19.41)
6-Thioguanine	12	2.20	140	6.03	2.7	<.001
		(<1.56-2.81)		(4.05-10.54)
Amsacrine	8	0.03	115	0.48	16.0	<.001
		(0.02-0.08)		(0.14-1.32)
2-Chloro-deoxyadenosine	6	0.016	103	0.020	1.3	.42
		(0.004-0.023)		(0.04-0.031)
Prednisolone	10	231.6	146	>250	>1.1	.006
		(95.9->250)		(>250->250)
Vincristine	11	0.13	135	2.99	23.0	<.001
		(<0.05-0.17)		(0.75-23.92)
L-Asparaginase	10	0.76	123	0.88	1.2	.83
		(0.33-1.19)		(0.23-1.48)
Busulfan	6	8.2	93	37.78	4.6	<.001
		(6.1-13.7)		(25.59-59.82)
4-hydroperoxy-ifosfamide	8	10.12	116	11.93	1.2	.47
		(4.69-12.31)		(5.79-14.78)
Methotrexate (TSI₅₀ short)	11	38.32	28	1.82	0.05	.003
		(32.62->40)		(0.63-18.38)
Methotrexate (TSI₅₀ cont)	9	0.08	27	0.05	0.6	.22
		(0.04-0.13)		(0.03-0.06)

LC₅₀ values are given in μg/mL. For MTX, the TSI₅₀ values (μM) are given after short-term (TSI₅₀ short) or long-term (TSI₅₀ cont) exposure.

RR, the median LC₅₀ value (for MTX, TSI₅₀) for non-DS AML divided by the median LC₅₀ value (for MTX, TSI₅₀) for DS AML.

P value derived from 2-tailed Mann-Whitney Utest.

L-asparaginase is given in IU/mL, not in μg/mL.

N indicates number of samples tested; P25-P75, 25^th and 75^th percentiles.